Results 81 to 90 of about 12,013,030 (353)

Drug Management of Visceral Pain: Concepts from Basic Research

Pain Research and Treatment, 2012
Visceral pain is experienced by 40% of the population, and 28% of cancer patients suffer from pain arising from intra- abdominal metastasis or from treatment.
Mellar P. Davis
semanticscholar   +1 more source

Erroneous formulation of delayed-release omeprazole capsules: alert for importing countries

BMC Pharmacology and Toxicology, 2017
Background Poor drug quality is a matter of serious concern, especially in countries where drug regulation and law enforcement are constrained by limited resources.
Mohammad Sofiqur Rahman, Naoko Yoshida, Hirohito Tsuboi, Tep Keila, Tey Sovannarith, Heng Bun Kiet, Eav Dararth, Theingi Zin, Tsuyoshi Tanimoto, Kazuko Kimura   +9 more
doaj   +1 more source

Characterization of Nanoparticles Using DSPE-PEG2000 and Soluplus

Colloids and Interfaces, 2020
The aim of this study was to evaluate the characterized hydration method to prepare nanoparticles using Soluplus, a block copolymer with amphipathic properties, and distearoyl phosphatidyl ethanolamine (DSPE)-PEG2000 owing to particle size distribution ...
Rina Takayama, Yutaka Inoue, Isamu Murata, Ikuo Kanamoto   +3 more
doaj   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Management of Submandibular Abcess in Patients with Multiple Drug Resistance (MDR-TB) [PDF]

, 2021
Dedy Pratama, drg Farah Asnely Putri, drg Seto Adiantoro   +2 more
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Cytochrome P450 Enzyme Inhibition and Herb-Drug Interaction Potential of Medicinal Plant Extracts Used for Management of Diabetes in Nigeria

, 2021
Ogochukwu Amaeze, Heather Eng, Lauren Horlbogen, Manthena V. S. Varma, Angela L. Slitt   +4 more
openalex   +2 more sources

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Drug stockpiling behavior and its impact on anxiety among the general public in the early stage after the lifting of China’s Zero-COVID policy: results from a web-based survey

Frontiers in Pharmacology
BackgroundOn 7 December 2022, China lifted most of the restrictions under the so-called zero-COVID policy due to factors like less toxicity of the new variants of the virus, leading to widespread infections throughout China.ObjectivesThis study aims to ...
Yu Huang, Shuiyang Xu, Xiang Zhao, Lei Wang, Qiaohong Lv, Suxian Wu, Qingqing Wu, Xuehai Zhang   +7 more
doaj   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source